IN8BIO, INC. Net Income (Loss) Available to Common Stockholders, Basic
IN8BIO, INC. (INAB) reported Net Income (Loss) Available to Common Stockholders, Basic of -$7.40 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-11-10
- IN8BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-09-30 was -$7.40M.
- IN8BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-06-30 was -$7.18M.
- IN8BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$6.14M.
- IN8BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$5.85M.
- IN8BIO, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$14.65M.
- IN8BIO, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$10.34M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$7.40M 10-Q · filed 2022-11-10 | -$14.58M derived: sum of 2 quarters · filed 2022-11-10 | -$20.72M 10-Q · filed 2022-11-10 | -$26.57M derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | -$7.18M 10-Q · filed 2022-08-12 | -$13.32M 10-Q · filed 2022-08-12 | -$19.17M derived: sum of 3 quarters · filed 2022-08-12 | -$22.56M derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-03-31 | -$6.14M 10-Q · filed 2022-05-12 | -$11.99M derived: sum of 2 quarters · filed 2022-05-12 | -$15.38M derived: sum of 3 quarters · filed 2022-11-10 | -$19.15M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-12-31 | -$5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$9.24M derived: sum of 2 quarters · filed 2022-11-10 | -$13.01M derived: sum of 3 quarters · filed 2022-11-10 | -$14.65M 10-K · filed 2022-03-17 |
| 2021-09-30 | -$3.39M 10-Q · filed 2022-11-10 | -$7.16M derived: sum of 2 quarters · filed 2022-11-10 | -$8.80M 10-Q · filed 2022-11-10 | -$13.25M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$3.77M 10-Q · filed 2022-08-12 | -$6.83M 10-Q · filed 2022-08-12 | -$9.86M derived: sum of 3 quarters · filed 2022-08-12 | -$12.04M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$3.07M 10-Q · filed 2022-05-12 | -$6.10M derived: sum of 2 quarters · filed 2022-05-12 | -$8.28M derived: sum of 3 quarters · filed 2022-05-12 | -$11.46M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$5.21M derived: sum of 2 quarters · filed 2022-03-17 | -$8.39M derived: sum of 3 quarters · filed 2022-03-17 | -$10.34M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$2.18M 10-Q · filed 2021-11-10 | -$5.36M derived: sum of 2 quarters · filed 2021-11-10 | -$7.31M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$3.18M 10-Q · filed 2021-09-10 | -$5.13M 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |